Next Article in Journal / Special Issue
Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining
Previous Article in Journal / Special Issue
Identification of a Potent Allosteric Inhibitor of Human Protein Kinase CK2 by Bacterial Surface Display Library Screening
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(1), 7; doi:10.3390/ph10010007

CK2—An Emerging Target for Neurological and Psychiatric Disorders

Department of Physiology, Pharmacology and Neuroscience, City University of New York School of Medicine, New York, NY 10031, USA
Ph.D. Programs in Biochemistry and Biology, The Graduate Center, City University of New York, New York, NY 10031, USA
Ph.D. Programs at Queens College, City University of New York, New York, NY 11367, USA
Author to whom correspondence should be addressed.
Academic Editor: Lorenzo A. Pinna
Received: 30 November 2016 / Revised: 20 December 2016 / Accepted: 30 December 2016 / Published: 5 January 2017
View Full-Text   |   Download PDF [643 KB, uploaded 5 January 2017]   |  


Protein kinase CK2 has received a surge of attention in recent years due to the evidence of its overexpression in a variety of solid tumors and multiple myelomas as well as its participation in cell survival pathways. CK2 is also upregulated in the most prevalent and aggressive cancer of brain tissue, glioblastoma multiforme, and in preclinical models, pharmacological inhibition of the kinase has proven successful in reducing tumor size and animal mortality. CK2 is highly expressed in the mammalian brain and has many bona fide substrates that are crucial in neuronal or glial homeostasis and signaling processes across synapses. Full and conditional CK2 knockout mice have further elucidated the importance of CK2 in brain development, neuronal activity, and behavior. This review will discuss recent advances in the field that point to CK2 as a regulator of neuronal functions and as a potential novel target to treat neurological and psychiatric disorders. View Full-Text
Keywords: CK2; neurodegeneration; synapse; signaling; CK2 inhibitors; GPCRs; CK2 substrates; CK2 knockout CK2; neurodegeneration; synapse; signaling; CK2 inhibitors; GPCRs; CK2 substrates; CK2 knockout

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Castello, J.; Ragnauth, A.; Friedman, E.; Rebholz, H. CK2—An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals 2017, 10, 7.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top